HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsUpgradesPrice Target
HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Crescent Biopharma (NASDAQ:CBIO) from Neutral to Buy and announces $36 price target.
HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Crescent Biopharma (NASDAQ:CBIO) from Neutral to Buy and announces $36 price target.